Introduction
How GLP-1 signaling supports brain health
Counteracting amyloid, tau, and neuroinflammation
Neuroprotective effects in experimental models
Early clinical trials show encouraging, but mixed results
Evidence from cardiovascular outcome trials and real-world studies
Limitations and challenges
Looking ahead: Ongoing trials and future opportunities
References
Further reading
From reduced amyloid and neuroinflammation in experimental models to mixed cognitive outcomes in clinical trials, emerging evidence is testing whether GLP-1 receptor agonists can move beyond metabolic therapy to become meaningful treatments for Alzheimer’s disease.
Image Credit: sebra / Shutterstock.com
Introduction
Type 2 diabetes (T2D) and insulin resistance are associated with an increased risk of cognitive decline and dementia, including Alzheimer’s disease (AD). This association has led researchers to investigate the therapeutic potential of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as semaglutide, for reducing dementia risk or slowing cognitive decline; however, a direct disease-modifying benefit in established AD remains unproven.4,5 GLP-1 RAs are approved for metabolic indications such as T2D and obesity rather than AD, so use specifically to prevent or treat AD remains off-label and investigational.3,4
Image Credit: sebra / Shutterstock.com
How GLP-1 signaling supports brain health
GLP-1 receptors are present in key brain regions involved in memory and cognition, thus linking their activation to cell survival, metabolism, and synaptic function. Preclinical data suggest that GLP-1 RAs may support synaptic function through activation of GLP-1 receptors in the central nervous system; they do not act through GLP-2 receptors.1,3
Preclinical studies suggest that GLP-1 RAs may support cerebral vascular integrity and blood-brain barrier integrity while modulating homeostasis in astrocytes, microglia, and other neuroimmune cells.3 Preclinical studies suggest that GLP-1 receptor activation may improve insulin signaling within the brain, promote neuronal survival, and support synaptic plasticity, both of which are critical processes involved in memory and learning.2,3
Counteracting amyloid, tau, and neuroinflammation
AD pathophysiology is characterized by the accumulation of amyloid-β (Aβ) proteins, which leads to the formation of amyloid plaques, as well as neurofibrillary tangles (NFTs) that arise from the hyperphosphorylation of tau proteins. As AD progresses, NFTs spread throughout the brain and result in nerve cell death.1
In animal models, GLP-1 RAs, particularly liraglutide, have reduced Aβ accumulation and tau protein-related changes in the brain. In preclinical models, these medications have demonstrated anti-inflammatory and antioxidant effects, including reductions in neuroinflammatory signaling and oxidative stress.1,2
GLP-1 RAs may improve brain energy metabolism in addition to synaptic function. In preclinical studies, GLP-1 RAs reduced amyloid accumulation and the levels of pro-inflammatory molecules like interleukin-1β (IL-1β). GLP-1 RAs were also found to preserve glucose metabolic rate and improve mitochondrial function, both of which enhance brain energy metabolism.2,4
Dulaglutide, although less frequently studied, has reduced tau phosphorylation and Aβ accumulation and improved cognitive outcomes in preclinical mouse models.1 Other GLP-1 RAs, including exendin-4, liraglutide, and semaglutide, have been linked experimentally to PI3K/AKT signaling and GSK3β phosphorylation, mechanisms that may reduce tau hyperphosphorylation and neuroinflammation.1
Neuroprotective effects in experimental models
In preclinical in vivo models, liraglutide and semaglutide show generally protective effects by reducing Aβ and tau protein levels, although findings for semaglutide are not uniformly positive across studies. In mice, knockout of GLP-1 receptors also resulted in reduced synaptic plasticity and memory formation, further supporting the neuroprotective potential of GLP-1 RAs, which should be studied in experimental models.1
In rat models, researchers induced AD using the toxin okadaic acid, which increases β-site amyloid precursor protein cleaving enzyme 1 (BACE1) levels. By reducing BACE1 levels, liraglutide treatment successfully reduced Aβ production, a mechanism that may limit amyloid plaque formation.
Similar findings have been observed in SH-SY5Y cells, a human neuroblastoma cell line often used as an in vitro model of neurons. Liraglutide treatment reduced BACE1 levels and increased cell sensitivity to insulin, which may restore healthier neuronal function.1
In higher animal models, prophylactic treatment with liraglutide before exposing monkeys’ brains to toxic Aβ proteins reduced abnormal tau protein formation and neurodegeneration, specifically of brain synapses. Similar but less potent effects have been observed with exenatide treatment.1
Novo Nordisk Alzheimer’s studies may reveal GLP-1 benefits | REUTERS
Early clinical trials show encouraging, but mixed results
Despite the therapeutic benefit of GLP-1 RA treatment observed in preclinical studies, early clinical trials have reported mixed or modest results. Although some studies suggest effects on brain structure or metabolic biomarkers, these surrogate or exploratory signals do not by themselves establish slowed clinical progression or disease modification.1,2
In a double-blind, placebo-controlled trial, AD patients received liraglutide for 26 weeks, which preserved cerebral glucose metabolism relative to placebo but did not significantly alter amyloid deposition or cognition.1,2
When used for the treatment of patients with mild to moderate AD dementia, liraglutide treatment for 12 months was associated with greater preservation of temporal lobe and total cortical volume and with better preservation of some cognitive measures than placebo.3 While clinical findings are mixed, additional trials with diverse populations and extended follow-up periods could improve the validity and generalizability of the findings.
A 2026 meta-analysis of randomized trials in non-diabetic participants found only a small improvement in global cognition and concluded that current evidence provides no convincing support for a clinically meaningful or disease-modifying effect of GLP-1 RAs.4
Evidence from cardiovascular outcome trials and real-world studies
A post hoc analysis of the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial, together with the SUSTAIN 6 and PIONEER 6 cardiovascular outcome trials, suggested that GLP-1 RAs may reduce dementia risk in T2D patients by up to 53%.3 An exploratory analysis of the REWIND trial similarly revealed that long-term treatment with the GLP-1 RA dulaglutide reduced cognitive decline in a cohort of individuals with T2D.3
Real-world evidence from studies conducted in the United States and Denmark indicates a reduced risk of up to 42% and 64% for dementia or AD, respectively, after using GLP-1 RAs for the management of T2D. However, a UK cohort study of adults aged 60 years and older with T2D found no significant reduction in all-cause dementia with GLP-1 RA initiation compared with DPP-4 inhibitor initiation in the intention-to-treat analysis (HR 0.95, 95% CI 0.87–1.04).
Continuous GLP-1 RA use was associated with a 21% lower risk (HR 0.79, 95% CI 0.64–0.97). SGLT2 inhibitor initiation, by contrast, was associated with a 14% lower dementia risk than DPP-4 inhibitor initiation (HR 0.86, 95% CI 0.79–0.94), while GLP-1 RA and SGLT2 inhibitor initiators had comparable risk.5
In a prospective open-label study of patients with T2D, liraglutide significantly improved learning, memory, object naming, and overall cognitive performance, as reflected by higher Mini-Mental State Examination (MMSE) scores.
In people with obesity, prediabetes, or diabetes, liraglutide improved short-term working memory and overall memory performance. Importantly, these results should be interpreted with caution, as the study cohort comprised individuals with metabolic disorders without a history of AD.2
The large-scale EXSCEL trial of T2D patients reported that exenatide reduced circulating levels of several inflammatory proteins involved in inflammation and vascular function, such as ficolin-2, plasminogen activator inhibitor-1 (PAI-1), and soluble vascular cell adhesion molecule-1 (sVCAM-1). These markers are often elevated in AD patients, but these biomarker findings are indirect and do not establish that exenatide reduces AD incidence or progression.1
Image Credit: Xavier Lorenzo / Shutterstock.com
Limitations and challenges
Although studies involving diabetic and non-diabetic participants have reported improvements in cognitive outcomes, it remains unclear whether GLP-1 RA therapy can improve cognitive function or mitigate AD progression in patients.
A 2026 meta-analysis of 14 randomized controlled trials involving 1,260 non-diabetic participants with AD, mild cognitive impairment, or Parkinson’s disease found a small improvement in global cognition (SMD 0.14, 95% CI 0.01–0.27), but estimated only a 1% probability that this represented a clinically important benefit.
The analysis also found poorer verbal fluency (SMD −0.43, 95% CI −0.79 to −0.08); because several neurodegenerative populations were pooled, these estimates are not specific to AD.4 GLP-1 RAs also significantly reduced weight and were associated with poorer tolerability and increased gastrointestinal adverse events.4
Observational dementia-risk estimates may also vary according to treatment persistence and analytic approach, reinforcing the need for caution when inferring causality from real-world associations.5 Thus, additional studies are needed to establish optimal drug type, dosing regimens, and treatment durations, as well as mechanistic investigations with comprehensive biomarker analysis to confirm the disease-modifying effects of GLP-1 RAs.2,4
Looking ahead: Ongoing trials and future opportunities
The EVOKE and EVOKE+ programs were designed to clarify the disease-modifying potential and efficacy of GLP-1 RAs when administered during the early stages of AD. In these randomized, double-blinded trials, researchers planned to assess clinical progression alongside biomarkers of AD-related pathogenic mechanisms, such as neuroinflammation, blood-brain barrier (BBB) integrity, synaptic function, and vascular integrity, during treatment with once-daily oral semaglutide versus placebo.3
If confirmed in larger trials, incretin-based therapies could be considered as adjunctive aids in early intervention or treatment of symptomatic AD.3 However, the evidence reviewed here does not establish a clinically meaningful disease-modifying benefit and does not support routine off-label use solely for AD neuroprotection.4
Looking ahead, GLP-1 RA medications have been associated with lower dementia risk in some T2D populations, but these observational findings should not be equated with proven preservation of cognitive function or brain health in patients with AD.3,5
References
- Corcoran, E., Kettlety, M., Mogul, U., et al. (2026). The effects of GLP-1 receptor agonists on Alzheimer's pathophysiology: A systematic review. Molecular and Cellular Neuroscience 137; 104091. DOI: 10.1016/j.mcn.2026.104091. https://www.sciencedirect.com/science/article/pii/S1044743126000217
- Chuansangeam, M., Phadungsaksawasdi, P., Park, H. J., & Yang, Y. H. (2025). Exploring the link between GLP-1 receptor agonists and dementia: A comprehensive review. Journal of Alzheimer's Disease Reports. DOI: 10.1177/25424823251342182. https://journals.sagepub.com/doi/10.1177/25424823251342182
- Cummings, J.L., Atri, A., Feldman, H. H., et al. (2025). evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer’s disease. Alzheimer’s Research & Therapy 17; 14. DOI: 10.1186/s13195-024-01666-7. https://link.springer.com/article/10.1186/s13195-024-01666-7
- Elghanam, Y. & Kim, E. (2026). Evaluating the clinical effects of GLP-1 receptor agonists for Alzheimer's and Parkinson's diseases using minimal clinically important difference: systematic review and meta-analysis. Archives of Pharmacal Research 49; 691-712. DOI: 10.1007/s12272-026-01615-y. https://link.springer.com/article/10.1007/s12272-026-01615-y
- Wu, C. Y., Alkabbani, W., Shah, B. R., et al. (2025). Comparative dementia risk with GLP1 receptor agonists, SGLT2 inhibitors, or DPP4 inhibitors: a population-based cohort study. Alzheimer’s Research & Therapy 17; 269. DOI: 10.1186/s13195-025-01929-x. https://link.springer.com/article/10.1186/s13195-025-01929-x
Further Reading
Last Updated: Aug 13, 2026